Ceci Zak, Sanofi-Aventis US
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system.
Ceci Zak
Vice President, General Therapeutics Marketing, Sanofi-Aventis US
The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system. This begs the question of how we can meet the future needs of the healthcare system—and how we can pay for it. We need to engage in the disruptive innovation that is critical to meet the evolving needs of the elderly.
In 10 years, I think the traditional pharma/bio model will have evolved from a treatment approach to one of providing total healthcare solutions, including preventative and diagnostic products, treatments, and maintenance support for patients. Thus, there will be a shift from our current target audiences (typically physicians) to the entire continuum of healthcare treaters.
I see my current roles as a senior-level businesswoman at Sanofi-Aventis and the president of the Healthcare Businesswomen's Association (HBA) as my great accomplishments. My role at HBA allows me to lead a board of directors that oversees numerous complex and successful events, such as WOTY (Woman of the Year), the Annual Leadership Conference, and other educational offerings provided by 14 chapters worldwide. During my presidential tenure at HBA, we are shoring up the strategic growth platform that will sustain the long-term viability of the organization. It's a wonderful way to give back!
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
